The ELARA Study
Status: Closed Enrollment Trials
Sponsor: REGENERON
Trial Summary
This study is researching aflibercept high dose (HD), referred to as “study drug”, with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.
The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
Condition(s) being studied:
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Age range
18 Years and Older
Trial date:
July 24, 2024 – August 26, 2025